Description du projet
Une nouvelle plateforme de culture cellulaire 3D destinée à remplacer les animaux dans les tests précliniques
Plus de 85 % des essais cliniques préliminaires échouent malgré les résultats prometteurs des tests précliniques in vitro. La principale raison est liée aux cultures cellulaires in vitro en 2D qui ne reproduisent pas l’environnement du corps vivant. Par conséquent, les tests précliniques sur les animaux demeurent une référence, malgré le coût et les préoccupations éthiques qui y sont associés. La société tchèque InoCure développe une plateforme unique d’échafaudage 3D pour la culture cellulaire in vitro intégrant un système d’administration de médicaments. Son objectif est d’améliorer sensiblement l’efficacité de la transposition préclinique à clinique tout en proposant une alternative aux modèles d’expérimentations animales. Le projet DifMATRIX, financé par l’UE, a pour objectif de réaliser l’étude de faisabilité, en évaluant la viabilité juridique, économique et technique de l’introduction de la technologie sur le marché.
Objectif
The use of in-vitro testing (in simulated environment) is the future of drug development, cancer research and medical research in general since it overcomes the practical and ethical issues associated with human and animal experimentation. However, as much as 85% of early clinical trials currently fail despite successful preclinical in-vitro testing; in the case of clinical cancer trials it is less than 8%. The main reason for such low success rates is that currently used 2D cells do not behave the same in living bodies as in cultures. As a consequence, animal testing continues to be widespread despite the associated cost and strong ethical concerns it raises. This is also extremely costly in time and resources which raise consumer prices for life-saving medications.
InoCure is addressing this problem with the DifMATRIX - a unique 3D scaffolding platform with drug delivery embedded system, for cell culture used in molecular biology and tissue engineering. DifMATRIX enables to simulate natural cell phenotype (in vivo) in the in-vitro environment. It redefines in-vitro preclinical testing standards, significantly improving preclinical-to-clinical translation efficiency and provide an alternative to animal testing models. The predicted impact of the project is to eliminate the animal testing phase from the drug development process.
The project is well aligned with new trends in cell and tissue culture supplier market. Globally, this market is witnessing significant growth due to increasing demand for biopharmaceuticals and increasing R&D in this field. The global cell/tissue engineering supplies market is expected to reach $28 billion in 2020. The market demand for DifMATRIX has been confirmed by customers currently using our passive InoMATRIX product, and by the letters of intent from prospective customers.
Following the proposed Phase 1, Inocure target is to apply for the Phase 2 project to scale-up the production and launch commercialisation of DifMATRIX.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesmolecular biology
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
11000 Praha
Tchéquie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.